Trade Cytokinetics Inc - CYTK CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.25 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Cytokinetics Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 66.28 |
| Open* | 66.78 |
| 1-Year Change* | 74.36% |
| Day's Range* | 66.78 - 68.47 |
| 52 wk Range | 25.98-110.25 |
| Average Volume (10 days) | 8.64M |
| Average Volume (3 months) | 72.63M |
| Market Cap | 8.11B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 98.05M |
| Revenue | 7.82M |
| EPS | -5.52 |
| Dividend (Yield %) | N/A |
| Beta | 0.74 |
| Next Earnings Date | Feb 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 66.28 | -1.22 | -1.81% | 67.50 | 67.81 | 65.51 |
| Apr 19, 2024 | 67.42 | 0.72 | 1.08% | 66.70 | 67.71 | 64.73 |
| Apr 18, 2024 | 66.93 | 0.28 | 0.42% | 66.65 | 68.11 | 66.65 |
| Apr 17, 2024 | 67.88 | -0.97 | -1.41% | 68.85 | 69.82 | 67.77 |
| Apr 16, 2024 | 68.89 | 1.39 | 2.06% | 67.50 | 70.45 | 66.65 |
| Apr 15, 2024 | 67.93 | -2.24 | -3.19% | 70.17 | 70.95 | 67.39 |
| Apr 12, 2024 | 71.50 | -1.67 | -2.28% | 73.17 | 73.39 | 70.55 |
| Apr 11, 2024 | 73.14 | -1.20 | -1.61% | 74.34 | 74.85 | 72.29 |
| Apr 10, 2024 | 74.31 | 1.86 | 2.57% | 72.45 | 74.73 | 72.22 |
| Apr 9, 2024 | 75.00 | 1.93 | 2.64% | 73.07 | 75.56 | 73.01 |
| Apr 8, 2024 | 74.08 | 0.95 | 1.30% | 73.13 | 74.33 | 72.45 |
| Apr 5, 2024 | 72.64 | 3.99 | 5.81% | 68.65 | 73.10 | 68.18 |
| Apr 4, 2024 | 69.15 | -2.24 | -3.14% | 71.39 | 72.11 | 68.66 |
| Apr 3, 2024 | 70.82 | 0.84 | 1.20% | 69.98 | 71.37 | 69.84 |
| Apr 2, 2024 | 70.91 | -0.29 | -0.41% | 71.20 | 72.51 | 70.20 |
| Apr 1, 2024 | 73.02 | 3.42 | 4.91% | 69.60 | 73.09 | 68.95 |
| Mar 28, 2024 | 70.00 | -1.05 | -1.48% | 71.05 | 71.74 | 69.90 |
| Mar 27, 2024 | 71.39 | 0.13 | 0.18% | 71.26 | 73.08 | 69.80 |
| Mar 26, 2024 | 71.10 | 2.36 | 3.43% | 68.74 | 74.06 | 68.20 |
| Mar 25, 2024 | 68.68 | 1.73 | 2.58% | 66.95 | 69.34 | 66.95 |
Cytokinetics Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, May 2, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 Cytokinetics Inc Earnings Release Q1 2024 Cytokinetics Inc Earnings ReleaseForecast -Previous - |
| Thursday, May 9, 2024 | ||
| Time (UTC) 17:00 | Country US
| Event Cytokinetics Inc Annual Shareholders Meeting Cytokinetics Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, May 15, 2024 | ||
| Time (UTC) 17:00 | Country US
| Event Cytokinetics Inc Annual Shareholders Meeting Cytokinetics Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, August 1, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 Cytokinetics Inc Earnings Release Q2 2024 Cytokinetics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 94.588 | 70.428 | 55.828 | 26.868 | 31.501 |
| Revenue | 94.588 | 70.428 | 55.828 | 26.868 | 31.501 |
| Total Operating Expense | 443.729 | 256.741 | 149.771 | 125.735 | 120.417 |
| Selling/General/Admin. Expenses, Total | 177.977 | 96.803 | 52.82 | 39.61 | 31.282 |
| Research & Development | 240.813 | 159.938 | 96.951 | 86.125 | 89.135 |
| Operating Income | -349.141 | -186.313 | -93.943 | -98.867 | -88.916 |
| Interest Income (Expense), Net Non-Operating | -39.814 | -29.001 | -33.347 | -22.825 | -17.373 |
| Net Income Before Taxes | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Net Income After Taxes | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Net Income Before Extra. Items | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Net Income | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Income Available to Common Excl. Extra. Items | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Income Available to Common Incl. Extra. Items | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Diluted Net Income | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Diluted Weighted Average Shares | 89.825 | 76.886 | 64.524 | 57.575 | 54.42 |
| Diluted EPS Excluding Extraordinary Items | -4.33014 | -2.80043 | -1.97275 | -2.11363 | -1.95312 |
| Diluted Normalized EPS | -4.0525 | -2.76401 | -1.97275 | -2.11363 | -1.95312 |
| Total Extraordinary Items | |||||
| Unusual Expense (Income) | 24.939 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.867 | 4.613 | 1.957 | 2.515 | 88.968 |
| Revenue | 0.867 | 4.613 | 1.957 | 2.515 | 88.968 |
| Total Operating Expense | 122.916 | 129.086 | 128.987 | 133.202 | 99.842 |
| Selling/General/Admin. Expenses, Total | 39.722 | 49.665 | 53.969 | 48.222 | 42.716 |
| Research & Development | 83.194 | 79.421 | 75.018 | 62.734 | 57.126 |
| Operating Income | -122.049 | -124.473 | -127.03 | -130.687 | -10.874 |
| Interest Income (Expense), Net Non-Operating | -6.588 | -6.816 | -10.35 | -11.623 | -8.946 |
| Net Income Before Taxes | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Net Income After Taxes | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Net Income Before Extra. Items | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Net Income | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Income Available to Common Excl. Extra. Items | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Income Available to Common Incl. Extra. Items | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Diluted Net Income | -128.637 | -131.289 | -137.38 | -142.31 | -19.82 |
| Diluted Weighted Average Shares | 95.755 | 95.164 | 94.715 | 93.758 | 85.731 |
| Diluted EPS Excluding Extraordinary Items | -1.3434 | -1.37961 | -1.45046 | -1.51784 | -0.23119 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.3434 | -1.37961 | -1.45046 | -1.28057 | -0.23119 |
| Unusual Expense (Income) | 0 | 0 | 0 | 22.246 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 795.186 | 535.672 | 474.221 | 233.752 | 207.674 |
| Cash and Short Term Investments | 782.577 | 471.638 | 464.06 | 225.112 | 198.731 |
| Cash & Equivalents | 65.582 | 112.666 | 82.985 | 36.433 | 42.256 |
| Short Term Investments | 716.995 | 358.972 | 381.075 | 188.679 | 156.475 |
| Total Receivables, Net | 0.147 | 51.819 | 4.42 | 5.163 | 6.785 |
| Accounts Receivable - Trade, Net | 0.147 | 51.819 | 4.42 | 5.163 | 6.785 |
| Prepaid Expenses | 12.462 | 12.215 | 5.741 | 3.477 | 2.158 |
| Total Assets | 1014.78 | 841.319 | 533.803 | 289.814 | 211.178 |
| Property/Plant/Equipment, Total - Net | 163.19 | 146.409 | 22.628 | 13.412 | 3.204 |
| Property/Plant/Equipment, Total - Gross | 180.284 | 162.598 | 47.269 | 37.607 | 27.065 |
| Accumulated Depreciation, Total | -17.094 | -16.189 | -24.641 | -24.195 | -23.861 |
| Long Term Investments | 46.708 | 152.05 | 36.954 | 42.65 | 0 |
| Other Long Term Assets, Total | 9.691 | 7.188 | 0.3 | ||
| Total Current Liabilities | 84.617 | 71.86 | 31.199 | 26.023 | 22.194 |
| Accounts Payable | 25.611 | 21.087 | 8.05 | 8.16 | 3.764 |
| Accrued Expenses | 56.925 | 49.233 | 22.1 | 16.739 | 15.757 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1 | 0.5 | 0 | 2.607 | |
| Other Current Liabilities, Total | 1.081 | 1.04 | 1.049 | 1.124 | 0.066 |
| Total Liabilities | 1122.68 | 597.456 | 420.42 | 300.751 | 185.244 |
| Total Long Term Debt | 610.618 | 143.638 | 135.713 | 129.257 | 39.806 |
| Long Term Debt | 609.618 | 142.838 | 135.713 | 129.257 | 39.806 |
| Other Liabilities, Total | 427.44 | 381.958 | 253.508 | 145.471 | 123.244 |
| Total Equity | -107.9 | 243.863 | 113.383 | -10.937 | 25.934 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.094 | 0.084 | 0.07 | 0.059 | 0.055 |
| Additional Paid-In Capital | 1481.59 | 1452.27 | 1105.47 | 853.341 | 768.703 |
| Retained Earnings (Accumulated Deficit) | -1585.99 | -1207.62 | -992.306 | -865.016 | -743.324 |
| Other Equity, Total | -3.59 | -0.869 | 0.149 | 0.679 | 0.5 |
| Total Liabilities & Shareholders’ Equity | 1014.78 | 841.319 | 533.803 | 289.814 | 211.178 |
| Total Common Shares Outstanding | 94.834 | 84.7995 | 71.0152 | 59.1721 | 54.7179 |
| Capital Lease Obligations | 1 | 0.8 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 561.416 | 586.575 | 680.629 | 795.186 | 884.275 |
| Cash and Short Term Investments | 539.239 | 565.722 | 663.962 | 782.577 | 867.664 |
| Cash & Equivalents | 99.692 | 68.639 | 101.616 | 65.582 | 106.238 |
| Short Term Investments | 439.547 | 497.083 | 562.346 | 716.995 | 761.426 |
| Total Receivables, Net | 2.499 | 0.985 | 1.006 | 0.147 | 2.294 |
| Accounts Receivable - Trade, Net | 2.499 | 0.985 | 1.006 | 0.147 | 2.294 |
| Prepaid Expenses | 19.678 | 19.868 | 15.661 | 12.462 | 14.317 |
| Total Assets | 740.614 | 779.899 | 889.815 | 1014.78 | 1075.96 |
| Property/Plant/Equipment, Total - Net | 155.543 | 158.114 | 160.661 | 163.19 | 155.378 |
| Long Term Investments | 15.468 | 26.871 | 40.406 | 46.708 | 28.544 |
| Other Long Term Assets, Total | 8.187 | 8.339 | 8.119 | 9.691 | 7.764 |
| Total Current Liabilities | 77.723 | 65.617 | 75.22 | 84.617 | 76.496 |
| Accounts Payable | 13.796 | 17.357 | 25.611 | 14.429 | |
| Accrued Expenses | 50.19 | 47.171 | 49.895 | 56.925 | 56.285 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1 | 1 | |||
| Other Current Liabilities, Total | 13.737 | 5.885 | 7.968 | 1.081 | 4.782 |
| Total Liabilities | 1179.42 | 1113.01 | 1118.83 | 1122.68 | 1091.94 |
| Total Long Term Debt | 609.019 | 609.78 | 610.623 | 610.618 | 609.73 |
| Long Term Debt | 609.019 | 609.78 | 610.623 | 609.618 | 608.53 |
| Other Liabilities, Total | 492.673 | 437.617 | 432.992 | 427.44 | 405.712 |
| Total Equity | -438.801 | -333.115 | -229.02 | -107.9 | -15.977 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.094 | 0.094 | 0.094 | 0.094 | 0.093 |
| Additional Paid-In Capital | 1537.32 | 1514.17 | 1489.81 | 1481.59 | 1438.1 |
| Retained Earnings (Accumulated Deficit) | -1975.34 | -1845.92 | -1717.28 | -1585.99 | -1448.61 |
| Other Equity, Total | -0.874 | -1.458 | -1.645 | -3.59 | -5.559 |
| Total Liabilities & Shareholders’ Equity | 740.614 | 779.899 | 889.815 | 1014.78 | 1075.96 |
| Total Common Shares Outstanding | 96.2518 | 95.9378 | 95.6093 | 94.834 | 94.578 |
| Capital Lease Obligations | 1 | 1.2 | |||
| Payable/Accrued | 12.561 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -388.955 | -215.314 | -127.29 | -121.692 | -106.289 |
| Cash From Operating Activities | -299.516 | -142.522 | 8.943 | -90.907 | -101.215 |
| Cash From Operating Activities | 5.814 | 2.276 | 1.831 | 1.293 | 1.239 |
| Non-Cash Items | 105.744 | 54.699 | 45.285 | 29.828 | 26.771 |
| Cash Taxes Paid | 0.001 | ||||
| Cash Interest Paid | 15.165 | 9.175 | 9.62 | 4.059 | 2.877 |
| Changes in Working Capital | -22.119 | 15.817 | 89.117 | -0.336 | -22.936 |
| Cash From Investing Activities | -262.134 | -147.777 | -196.515 | -74.707 | 5.133 |
| Capital Expenditures | -11.335 | -48.872 | -11.052 | -2.619 | -0.889 |
| Other Investing Cash Flow Items, Total | -250.799 | -98.905 | -185.463 | -72.088 | 6.022 |
| Cash From Financing Activities | 516.166 | 319.98 | 234.124 | 159.791 | 13.132 |
| Financing Cash Flow Items | 31.924 | 7.931 | 7.507 | -11.993 | 3.234 |
| Issuance (Retirement) of Stock, Net | 0 | 312.049 | 226.617 | 36.214 | 0 |
| Issuance (Retirement) of Debt, Net | 484.242 | 0 | 0 | 135.57 | 9.898 |
| Net Change in Cash | -45.484 | 29.681 | 46.552 | -5.823 | -82.95 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -131.289 | -388.955 | -251.575 | -109.265 | -89.445 |
| Cash From Operating Activities | -122.286 | -299.516 | -201.326 | -117.286 | -26.811 |
| Cash From Operating Activities | 1.848 | 5.814 | 4.156 | 2.748 | 1.341 |
| Non-Cash Items | 25.392 | 105.744 | 86.135 | 41.684 | 20.574 |
| Changes in Working Capital | -18.237 | -22.119 | -40.042 | -52.453 | 40.719 |
| Cash From Investing Activities | 165.497 | -262.134 | -291.383 | 0.989 | -64.279 |
| Capital Expenditures | -0.402 | -11.335 | -8.13 | -1.799 | -0.942 |
| Other Investing Cash Flow Items, Total | 165.899 | -250.799 | -283.253 | 2.788 | -63.337 |
| Cash From Financing Activities | -7.177 | 516.166 | 486.281 | 97.262 | 93.846 |
| Financing Cash Flow Items | -6.97 | 31.924 | 1.934 | -4.253 | -7.936 |
| Net Change in Cash | 36.034 | -45.484 | -6.428 | -19.035 | 2.756 |
| Issuance (Retirement) of Stock, Net | 0 | 0 | |||
| Issuance (Retirement) of Debt, Net | -0.207 | 484.242 | 484.347 | 101.515 | 101.782 |
| Cash Interest Paid | 0.04 | 15.165 | 5.555 | 5.474 | 2.714 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cytokinetics Inc Company profile
About Cytokinetics, Inc.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cytokinetics, Inc. revenues increased 26% to $70.4M. Net loss increased 69% to $215.3M. Revenues reflect License revenues increase of 50% to $54.9M, Milestone revenues increase of 79% to $5M. Higher net loss reflects Research and development increase of 66% to $149.5M (expense), Other General and administrative increase of 91% to $80.4M (expense).
Equity composition
Common Stock $.001 Par, 02/11, 170M auth., 66,910,100 o/s. Insiders and Straegic holds 9.82%. 4/29/04, 5,800,000 shares @ $13 per share by Goldman, Sachs & Co. 25/13, 1-for-6 Reverse Stock split.
| Industry: | Bio Therapeutic Drugs |
350 Oyster Point Boulevard
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com